Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

Inclusion Criteria: * Adult patients aged 18 years or older. * Patients with diagnosis of NVAF. * Patients treated with rivaroxaban from at least six months prior to the study inclusion. * Patients who have been given appropriate information about the study objectives and procedures and who have given their written informed consent. Exclusion Criteria: * Patients participating in an investigational program with interventions outside of routine clinical practice. * Patients who initiate treatment with rivaroxaban after the start of the study inclusion period. * Prosthetic heart valves or the presence of any severe valvulopathies. * Patients with severe cognitive impairment. * Patients with chronic infections (HIV infection, hepatitis C virus, hepatitis B virus) or systemic autoimmune diseases. * Patients with active cancer. * Patients with liver insufficiency (eg. cirrhosis).